Home The Word Brain	My Amedeo FAQ Privacy About
	Explore this week’s CC Journal Club 90‑sec video • 4‑min audio • paper abstracts

HIV Infection

Free Subscription Articles published in Antimicrob Agents Chemother Retrieve available abstracts of 27 articles: HTML format

Single Articles

April 2025
1. SAWE S, Tsirizani L, Court R, Gausi K, et al
   The effect of pregnancy on the population pharmacokinetics of levofloxacin in South Africans with rifampicin-resistant tuberculosis.
   Antimicrob Agents Chemother. 2025 Apr 1:e0162624. doi: 10.1128/aac.01626.
   PubMed     Abstract available
   
   
   March 2025
2. MATTHEWS RP, Patel M, Liu W, Liu Y, et al
   Pharmacokinetics of islatravir in participants with moderate hepatic impairment.
   Antimicrob Agents Chemother. 2025 Mar 5:e0155324. doi: 10.1128/aac.01553.
   PubMed     Abstract available
   
   
   February 2025
3. LAZZARO A, Recchia GE, Alessi F, Santinelli L, et al
   Efficacy, safety, and anti-inflammatory properties of the switch to a doravirine-based regimen among antiretroviral-experienced elderly people living with HIV-1: the DORAGE cohort.
   Antimicrob Agents Chemother. 2025 Feb 18:e0081524. doi: 10.1128/aac.00815.
   PubMed     Abstract available
   
   
   January 2025
4. FILLGROVE KL, Matthews RP, Lu B, Liang Y, et al
   Nonclinical and clinical characterization of the absorption, metabolism, and excretion of islatravir.
   Antimicrob Agents Chemother. 2025 Jan 14:e0103024. doi: 10.1128/aac.01030.
   PubMed     Abstract available
   
   
   December 2024
5. NDZAMBA B, Denti P, McIlleron H, Smith P, et al
   Pharmacokinetics of ethambutol and weight banded dosing in South African adults newly diagnosed with tuberculosis and HIV.
   Antimicrob Agents Chemother. 2024 Dec 23:e0120024. doi: 10.1128/aac.01200.
   PubMed     Abstract available
   
   
   October 2024
6. HAN K, D'Amico RD, Spreen WR, Ford SL, et al
   Population pharmacokinetics of cabotegravir following intramuscular thigh injections in adults with and without HIV.
   Antimicrob Agents Chemother. 2024 Oct 23:e0088024. doi: 10.1128/aac.00880.
   PubMed     Abstract available
   
   
   September 2024
7. MARZINKE MA, Han K, Hanscom B, Guo X, et al
   Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084.
   Antimicrob Agents Chemother. 2024 Sep 23:e0099424. doi: 10.1128/aac.00994.
   PubMed     Abstract available
   
   
   
8. SHIN Y, Park CM, Kim D-E, Kim S, et al
   Discovery of new acetamide derivatives of 5-indole-1,3,4-oxadiazol-2-thiol as inhibitors of HIV-1 Tat-mediated viral transcription.
   Antimicrob Agents Chemother. 2024 Sep 4:e0064324. doi: 10.1128/aac.00643.
   PubMed     Abstract available
   
   
   
9. POLI ANR, Tietjen I, Nandwana NK, Cassel J, et al
   Design of novel and highly selective SARS-CoV-2 main protease inhibitors.
   Antimicrob Agents Chemother. 2024 Sep 3:e0056224. doi: 10.1128/aac.00562.
   PubMed     Abstract available
   
   
   August 2024
10. ZANG X, Ankrom W, Kraft WK, Vargo R, et al
    Intracellular islatravir-triphosphate half-life supports extended dosing intervals.
    Antimicrob Agents Chemother. 2024 Aug 6:e0045824. doi: 10.1128/aac.00458.
    PubMed     Abstract available
    
    
    July 2024
11. BAE J, Tantawy M, Gong Y, Langaee T, et al
    Pharmacogenetic determinants of tenofovir diphosphate and lamivudine triphosphate concentrations in people with HIV/HBV coinfection.
    Antimicrob Agents Chemother. 2024 Jul 30:e0054924. doi: 10.1128/aac.00549.
    PubMed     Abstract available
    
    
    
12. SEMERE GEBREYESUS M, Wasmann RE, McIlleron H, Oladokun R, et al
    Population pharmacokinetics of rifabutin among HIV/TB co-infected children on lopinavir/ritonavir-based antiretroviral therapy.
    Antimicrob Agents Chemother. 2024 Jul 22:e0035424. doi: 10.1128/aac.00354.
    PubMed     Abstract available
    
    
    
13. GIGANTE V, Alm RA, Melchiorri D, Rocke T, et al
    Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps.
    Antimicrob Agents Chemother. 2024 Jul 15:e0053524. doi: 10.1128/aac.00535.
    PubMed     Abstract available
    
    
    
14. VAN GULCK E, Pardons M, Nijs E, Verheyen N, et al
    Correction for Van Gulck et al., "A truncated HIV Tat demonstrates potent and specific latency reversal activity".
    Antimicrob Agents Chemother. 2024 Jul 2:e0081924. doi: 10.1128/aac.00819.
    PubMed    
    
    
    
15. MATTHEWS RP, Liu Y, Matthews C, Butterfield KL, et al
    Thorough QT/QTc study to evaluate the effect of a single supratherapeutic dose of islatravir on QTc interval prolongation in healthy adults.
    Antimicrob Agents Chemother. 2024 Jul 2:e0046424. doi: 10.1128/aac.00464.
    PubMed     Abstract available
    
    
    June 2024
16. DIAMOND TL, Goh SL, Ngo W, Rodriguez S, et al
    No antagonism or cross-resistance and a high barrier to the emergence of resistance in vitro for the combination of islatravir and lenacapavir.
    Antimicrob Agents Chemother. 2024 Jun 12:e0033424. doi: 10.1128/aac.00334.
    PubMed     Abstract available
    
    
    
17. MOTTA I, Cusinato M, Ludman AJ, Lachenal N, et al
    How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
    Antimicrob Agents Chemother. 2024 Jun 6:e0053624. doi: 10.1128/aac.00536.
    PubMed     Abstract available
    
    
    
18. RAINES SLM, Falcinelli SD, Peterson JJ, Van Gulck E, et al
    Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets.
    Antimicrob Agents Chemother. 2024 Jun 3:e0020124. doi: 10.1128/aac.00201.
    PubMed     Abstract available
    
    
    May 2024
19. PANJASAWATWONG N, Avihingsanon A, Menetrey C, Ribeiro I, et al
    Population pharmacokinetics of ravidasvir in adults with chronic hepatitis C virus infection and impact of antiretroviral treatment.
    Antimicrob Agents Chemother. 2024 May 20:e0000824. doi: 10.1128/aac.00008.
    PubMed     Abstract available
    
    
    
20. BECKEN B, Dousa KM, Johnson JL, Holland SM, et al
    Dual beta-lactam for treatment of pulmonary Mycobacterium abscessus in a child.
    Antimicrob Agents Chemother. 2024 May 17:e0031924. doi: 10.1128/aac.00319.
    PubMed     Abstract available
    
    
    
21. HAN K, Patel P, McCallister S, Rinehart AR, et al
    Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP.
    Antimicrob Agents Chemother. 2024 May 6:e0147523. doi: 10.1128/aac.01475.
    PubMed     Abstract available
    
    
    April 2024
22. KENGO A, Nabeemeeah F, Denti P, Sabet R, et al
    Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2024 Apr 10:e0158323. doi: 10.1128/aac.01583.
    PubMed     Abstract available
    
    
    
23. CHANDASANA H, Singh R, Adkison K, Ait-Khaled M, et al
    Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1.
    Antimicrob Agents Chemother. 2024 Apr 8:e0150423. doi: 10.1128/aac.01504.
    PubMed     Abstract available
    
    
    March 2024
24. COSSU MV, D'Avolio A, Gervasoni C, Giacomelli A, et al
    Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV.
    Antimicrob Agents Chemother. 2024 Mar 27:e0017524. doi: 10.1128/aac.00175.
    PubMed    
    
    
    
25. HAN K
    Reply to Cossu et al., "Switching to deltoid intramuscular injections maintains therapeutic trough concentrations of rilpivirine and cabotegravir in people with HIV".
    Antimicrob Agents Chemother. 2024 Mar 27:e0020424. doi: 10.1128/aac.00204.
    PubMed    
    
    
    
26. WANG C, Yu X, Ke Y, Fu Y, et al
    Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study.
    Antimicrob Agents Chemother. 2024 Mar 14:e0166823. doi: 10.1128/aac.01668.
    PubMed     Abstract available
    
    
    
27. JOGIRAJU V, Weber E, Hindman J, West S, et al
    Pharmacokinetics of long-acting lenacapavir in participants with hepatic or renal impairment.
    Antimicrob Agents Chemother. 2024 Mar 8:e0134423. doi: 10.1128/aac.01344.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.